MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.leukres.2021.106627

Медицинская библиотека · Leukemia research · 2021

Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study.

Yasuda Shunichiro, Najima Yuho, Konishi Tatsuya, Yamada Yuta, Nagata Akihito, Takezaki Toshiaki, Kaito Satoshi, Kurosawa Shuhei, Sakaguchi Masahiro, Harada Kaito, Shingai Naoki, Yoshioka Kosuke, Inamoto Kyoko, Mukae Junichi, Toya Takashi, Igarashi Aiko, Shimizu Hiroaki, Kobayashi Takeshi, Kakihana Kazuhiko, Sakamaki Hisashi, Kawamata Norihiko, Ohashi Kazuteru, Doki Noriko

СтатьяПеревод пока не подготовлен

Аннотация

Although the indications for allogeneic hematopoietic stem cell transplantation (allo-HSCT) as a treatment for T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) and Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (B-ALL) are similar, few studies have compared its outcomes for T-ALL/LBL and Ph-negative B-ALL. The clinical data of 28 patients with T-ALL, 16 with T-LBL, and 99 with Ph-negative B-ALL who underwent the first allo-HSCT from 2000 to 2019 were retrospectively analyzed. Complete remission (CR) rates at allo-HSCT were 79 %, 63 %, and 75 % for T-ALL, T-LBL, and B-ALL, respectively; the 3-year overall survival (OS) rates were 55.7 %, 56.2 %, and 58.6 %, respectively (p = 0.92). Univariate analysis revealed that disease subtypes were not significantly associated with OS (B-ALL vs. T-ALL: hazard ratio [HR]=0.89, p = 0.70; T-LBL vs. T-ALL: HR=0.87, p = 0.75), and CR at allo-HSCT was the only prognostic factor for OS (HR=0.25, p < 0.001). Multivariate analysis demonstrated that CR at allo-HSCT was the only predictor of OS (HR=0.24, p < 0.001). In all three disease subtypes, patients in CR at allo-HSCT tended to have a lower cumulative incidence of relapse than did those in non-CR (T-ALL: 13.6 % vs. 50.0 %, p = 0.10; T-LBL: 20.0 % vs. 50.0 %, p = 0.21; B-ALL: 10.0 % vs. 56.0 %, p < 0.01). Thus, the outcomes of allo-HSCT for T-ALL/LBL were comparable to those of Ph-negative B-ALL. Irrespective of the disease subtypes, achieving CR before allo-HSCT was associated with a favorable OS. Further advances in chemotherapy before allo-HSCT and defining the optimal timing of allo-HSCT would improve the prognosis of patients with T-ALL/LBL.

Для цитирования: Yasuda Shunichiro, Najima Yuho, Konishi Tatsuya, Yamada Yuta, Nagata Akihito, Takezaki Toshiaki, Kaito Satoshi, Kurosawa Shuhei, Sakaguchi Masahiro, Harada Kaito, Shingai Naoki, Yoshioka Kosuke, Inamoto Kyoko, Mukae Junichi, Toya Takashi, Igarashi Aiko, Shimizu Hiroaki, Kobayashi Takeshi, Kakihana Kazuhiko, Sakamaki Hisashi, Kawamata Norihiko, Ohashi Kazuteru, Doki Noriko. Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study.. Leukemia research. 2021. DOI: 10.1016/j.leukres.2021.106627.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.